[go: up one dir, main page]

PE20000543A1 - Composiciones estabilizadas de quinapril y procedimiento para prepararlas - Google Patents

Composiciones estabilizadas de quinapril y procedimiento para prepararlas

Info

Publication number
PE20000543A1
PE20000543A1 PE1999000475A PE00047599A PE20000543A1 PE 20000543 A1 PE20000543 A1 PE 20000543A1 PE 1999000475 A PE1999000475 A PE 1999000475A PE 00047599 A PE00047599 A PE 00047599A PE 20000543 A1 PE20000543 A1 PE 20000543A1
Authority
PE
Peru
Prior art keywords
cyclobraliphatic
cycling
refers
quinapril
preparing
Prior art date
Application number
PE1999000475A
Other languages
English (en)
Inventor
Jane Ellen Daniel
Michael Ray Harris
Gerard Clifford Hokanson
Jay Weiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20000543(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20000543A1 publication Critical patent/PE20000543A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a)UN INHIBIDOR DE ENZIMA CONVERSORA DE ANGIOTENSINA (ACE) QUE ES SUSCEPTIBLE DE CICLACION, HIDROLISIS, DECOLORACION, DE FORMULA I, DONDE A ES UN ANILLO CICLOALIFATICO DE 5, 6 o 7 MIEMBROS, ANILLO BENCENO OPCIONALMENTE SUSTITUIDO CON ALCOXI C1-C4 O ESTA AUSENTE; n ES 0-1; R ES H, ALQUILO C1-C5, SIENDO DE PREFERENCIA EL INHIBIDOR CLORHIDRATO DE QUINAPRIL, ENALAPRIL, INDOLAPRIL; b)DE 1% A 90% DE UN ESTABILIZADOR TAL COMO OXIDO DE MAGNESIO PARA RETARDAR LA CICLACION Y LA DECOLORACION, c)UN AGENTE PARA INHIBIR LA HIDROLISIS QUE PUEDE SER UN SACARIDO TAL COMO MANITOL O LACTOSA, d)UNA DROGA ADICIONAL, e)LIGANTES, DESINTEGRANTES Y LUBRICANTES. TAMBIEN SE REFIERE A UN PROCESO PARA ESTABILIZAR LA COMPOSICION. LOS COMPUESTOS INHIBIDORES DE ACE SON UTILES COMO ANTIHIPERTENSIVOS
PE1999000475A 1998-06-05 1999-06-04 Composiciones estabilizadas de quinapril y procedimiento para prepararlas PE20000543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05

Publications (1)

Publication Number Publication Date
PE20000543A1 true PE20000543A1 (es) 2000-08-10

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000475A PE20000543A1 (es) 1998-06-05 1999-06-04 Composiciones estabilizadas de quinapril y procedimiento para prepararlas

Country Status (32)

Country Link
US (3) US6417196B1 (es)
EP (1) EP1083931B1 (es)
JP (1) JP3727848B2 (es)
KR (1) KR20010052557A (es)
CN (1) CN1144598C (es)
AR (1) AR019150A1 (es)
AT (1) ATE295184T1 (es)
AU (1) AU755616B2 (es)
BR (1) BR9910947A (es)
CA (1) CA2330581A1 (es)
CO (1) CO5011043A1 (es)
DE (1) DE69925269T2 (es)
ES (1) ES2242398T3 (es)
GT (1) GT199900079A (es)
HK (1) HK1038879B (es)
HN (1) HN1999000088A (es)
HU (1) HUP0102260A3 (es)
ID (1) ID27398A (es)
IL (1) IL139590A0 (es)
IS (1) IS2270B (es)
MY (1) MY119667A (es)
NO (1) NO20006148D0 (es)
NZ (1) NZ508544A (es)
PA (1) PA8475001A1 (es)
PE (1) PE20000543A1 (es)
PL (1) PL344586A1 (es)
SV (1) SV1999000072A (es)
TR (1) TR200003600T2 (es)
TW (1) TW565455B (es)
UY (1) UY25546A1 (es)
WO (1) WO1999062560A1 (es)
ZA (1) ZA200006537B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102260A3 (en) * 1998-06-05 2002-12-28 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU5881001A (en) * 2000-05-24 2001-12-03 Otsuka Pharma Co Ltd Method of stabilizing preparation
US20050118259A1 (en) * 2002-01-15 2005-06-02 Renir Eyjolfsson Formulations of quinapril and related ace nhibitors
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
US7278982B2 (en) 2003-03-27 2007-10-09 Bioactis Limited Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
PT1635792E (pt) * 2003-06-26 2009-05-15 Teva Pharma Composições farmacêuticas estáveis de derivados do ácido 2-aza-biciclo[3.3.0]octano-3-carboxílico
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
RU2008145115A (ru) * 2006-04-19 2010-05-27 Тева Фармасьютикл Индастриес Лтд. (Il) Стабильные фармацевтические композиции производственных соединений 2-аза-бицикло[3.3.0]-октан-3-карбоновой кислоты
US20100035955A1 (en) * 2006-06-30 2010-02-11 Panagiotis Keramidas Stabilised Composition Comprising ACE Inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
CN101668544B (zh) * 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) * 1967-05-16 Method of preparing magnesia
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
HUP0102260A3 (en) * 1998-06-05 2002-12-28 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
NO20006148L (no) 2000-12-04
JP2002516881A (ja) 2002-06-11
DE69925269T2 (de) 2006-02-23
HK1038879A1 (en) 2002-04-04
US6417196B1 (en) 2002-07-09
PA8475001A1 (es) 2000-09-29
US20060106057A1 (en) 2006-05-18
US7015232B2 (en) 2006-03-21
HUP0102260A2 (hu) 2002-03-28
IS5712A (is) 2000-11-10
ES2242398T3 (es) 2005-11-01
BR9910947A (pt) 2001-03-06
ZA200006537B (en) 2001-11-12
CN1144598C (zh) 2004-04-07
CO5011043A1 (es) 2001-02-28
HN1999000088A (es) 2000-02-10
CA2330581A1 (en) 1999-12-09
AU755616B2 (en) 2002-12-19
AR019150A1 (es) 2001-12-26
IS2270B (is) 2007-07-15
HK1038879B (zh) 2004-10-08
MY119667A (en) 2005-06-30
CN1304322A (zh) 2001-07-18
EP1083931A1 (en) 2001-03-21
GT199900079A (es) 2000-11-25
NZ508544A (en) 2002-10-25
EP1083931B1 (en) 2005-05-11
PL344586A1 (en) 2001-11-05
TR200003600T2 (tr) 2001-04-20
ATE295184T1 (de) 2005-05-15
NO20006148D0 (no) 2000-12-04
US20020161020A1 (en) 2002-10-31
UY25546A1 (es) 1999-09-27
KR20010052557A (ko) 2001-06-25
JP3727848B2 (ja) 2005-12-21
ID27398A (id) 2001-04-05
WO1999062560A1 (en) 1999-12-09
DE69925269D1 (de) 2005-06-16
IL139590A0 (en) 2002-02-10
HUP0102260A3 (en) 2002-12-28
AU3979399A (en) 1999-12-20
SV1999000072A (es) 2000-05-04
TW565455B (en) 2003-12-11

Similar Documents

Publication Publication Date Title
PE20000543A1 (es) Composiciones estabilizadas de quinapril y procedimiento para prepararlas
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
BG106020A (en) Inhibitors of impdh enzyme
NO991494D0 (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
BR0207871A (pt) Composição para liberar bisfosfonato para um alvo
MY120064A (en) Indole derivatives as inhibitors or factor xa
ATE273305T1 (de) Thrombin-inhibitoren
PE20011001A1 (es) Compuestos heterociclicos como inhibidores del intercambio de sodio/protones
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
TN2009000544A1 (fr) Derives de benzimidazole
AU3664401A (en) Platelet adp receptor inhibitors
ECSP088172A (es) Metodos para tratar la epileptogenesis
CO6190539A2 (es) Composiciones de carbamato fenilalquilo
SV1997000026A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
BR0207644A (pt) Compostos de carbamato para uso na prevenção ou no tratamento de distúrbio bipolar
BR0213731A (pt) Compostos de silìcio
MA31775B1 (fr) Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
PT1305082E (pt) Compostos de carbamato para utilizacao na prevencao ou tratamento da dor neuropatica e dor associada a cefaleia de salvas e enxaqueca
NO983511L (no) Difenylstilbener som pro-legemidler til COX-2-inhibitorer
AR007965A1 (es) Composiciones plaguicidas que contienen diarilhidrazonas, dichas diarilhidrazonas, su preparacion, un metodo para combatir plagas con lasmismas, el material de propagacion de plantas tratado con dichos compuestos y su uso para controlar plagas.
BR0107282A (pt) Composto, composição farmacêutica e métodos para prevenir ou tratar uma condição em um mamìfero e para inibir a coagulação de amostras biológicas
MA29567B1 (fr) (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl) amino]-1,3-thiazol-4(5h)-one
RU95110868A (ru) Новые конденсированные производные тиазола, способ его получения и его фармацевтическая композиция

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed